Comparing Farxiga vs Januvia
| Farxiga (dapagliflozin) | Januvia (sitagliptin) |
|
|---|
| Farxiga (dapagliflozin) | Januvia (sitagliptin) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Farxiga is an oral medication that is used alongside diet and exercise to lower blood glucose levels in adults and children aged 10 years and older with type 2 diabetes. It may also be used to... View more |
Prescription only
Januvia is a DPP-4 inhibitor that is used in addition to other medications for the treatment of type 2 diabetes. Rarely, it may cause joint pain, skin reactions, pancreatitis, or an allergic... View more |
Related suggestions Type 2 Diabetes
|
|||||||
| More about Farxiga (dapagliflozin) | More about Januvia (sitagliptin) | ||||||||
| Ratings & Reviews | |||||||||
|
Farxiga has an average rating of 4.6 out of 10 from a total of 162 ratings on Drugs.com. 26% of reviewers reported a positive effect, while 47% reported a negative effect. |
Januvia has an average rating of 4.5 out of 10 from a total of 139 ratings on Drugs.com. 29% of reviewers reported a positive effect, while 53% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Farxiga side effects |
View all Januvia side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Farxiga prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
|
N/A |
Other sitagliptin brands include: Brynovin, Zituvio | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
12.9 hours |
12.4 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 372 drugs are known to interact with Farxiga:
|
A total of 296 drugs are known to interact with Januvia:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
January 08, 2014 |
October 16, 2006 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Mounjaro
Mounjaro is used to treat type 2 diabetes in adults. It is a subcutaneous injection that can be ...
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Lasix
Lasix is a loop diuretic used to treat fluid retention from heart, liver, or kidney conditions, and ...
Entresto
Entresto is an oral combination heart medication that contains two blood pressure-lowering ...
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Lantus
Lantus is a long acting form of insulin used to treat type 1 or type 2 diabetes. Learn about side ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.